98%
921
2 minutes
20
To systematically determine the diagnostic accuracy of digital breast tomosynthesis (DBT) in combination with digital mammography (DM) compared with DM alone for breast cancer. We searched multiple English and Chinese databases from January 2010 to October 2023. Eligible diagnostic studies comparing DBT/DM with DM alone for breast cancer in women were included. QUADAS-2 tool was used to assess the risk of bias. The summary sensitivity, specificity, and diagnostic odds ratio (DOR) were estimated using a bivariate model. 27 studies with 45,694 individuals and 59,493 breast lesions were included. The pooled sensitivity and specificity of DBT/DM were 87% (95% confidence interval [CI], 84-90%) and 84% (95% CI, 78-88%), respectively. These values were higher than those of DM alone, with pooled sensitivity of 76% (95% CI, 72-79%) and specificity of 80% (95% CI, 73-86%). The pooled DORs for DBT/DM and DM alone were 34.74 (95% CI, 22.18-54.39) and 12.96 (95% CI, 8.80-19.08), respectively. Additionally, adding DBT to DM improved diagnostic performance more significantly in Asians (DORs, 59.47 vs. 16.10) than in Westerners (DORs, 19.48 vs. 10.30). Meta-regression analysis revealed that country, reference standard, and published language were significant factors (P < 0.05) affecting heterogeneity for DBT/DM. This meta-analysis demonstrated that DBT/DM has higher diagnostic accuracy than DM alone for breast cancer. Diagnosing breast cancer with DBT/DM significantly increased sensitivity and slightly increased specificity compared with DM alone. Furthermore, adding DBT to DM increased diagnostic performance more significantly in Asians than in Westerners.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241149 | PMC |
http://dx.doi.org/10.1007/s10238-025-01789-7 | DOI Listing |
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Obstet Gynecol
July 2025
Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFIn Vitro Cell Dev Biol Anim
September 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.
S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.